Agilent Technologies Inc. announced that Pascal Soriot, CEO of AstraZeneca, and Judy Gawlik Brown, founder and CEO of Downtown Advisory, have been elected to its Board of Directors, effective May 21, 2025.
Soriot and Gawlik Brown bring decades of global leadership experience across the pharmaceutical, biotechnology, and health-care sectors, with proven track records in strategy, innovation, operations, and finance.
Pascal Soriot has led AstraZeneca as CEO since 2012, guiding the company’s transformation into a global leader in science-driven innovation with a strong pipeline and substantial growth. He has previously held other executive roles, including CEO of Genentech and Chief Operating Officer of Roche’s pharmaceutical division. His global career has spanned leadership roles in Australia, Europe, Japan, and the U.S., and he has served on several industry boards.
Judy Gawlik Brown is a seasoned financial and strategic adviser with deep experience across the life-sciences and consumer-health industries as both an executive and board member. Also, her career has included international postings in Germany and Italy. Through her consultancy, Downtown Advisory, she advises health-care and biotech companies on growth and strategy. She previously served as Chief Financial Officer of Perrigo Company, Senior Vice President of Finance at Amgen and subsequently Senior Vice President of Corporate Affairs; she also has held other senior-leadership roles overseeing financial and corporate-strategy functions.
“Pascal brings decades of global pharmaceutical-industry leadership experience, which will be invaluable to Agilent at the start of our three-year Ignite Transformation,” said Padraig McDonnell, Agilent president and CEO. “Judy’s experience as a financial executive and as a director of several high-performing health-care organizations makes her a valuable addition to the Agilent Board as we seek to grow Agilent. We’re delighted to welcome both Judy and Pascal to our Board.”
Comments powered by CComment